Abstract
Myocardial ischemia occurs for a mismatch between blood flow and metabolic requirements, when the rate of oxygen and metabolic substrates delivery to the myocardium is insufficient to meet the myocardial energy requirements for a given myocardial workload. During ischemia, substantial changes occur in cardiac energy metabolism, as a consequence of the reduced oxygen availability. Some of these metabolic changes are beneficial and may help the heart adapt to the ischemic condition. However, most of the changes are maladaptive and contribute to the severity of the ischemic injury leading stunned or hibernating myocardium, cell death and ultimately to contractile disfuction. Dramatic changes in cardiac metabolism and contractile function, also occur during myocardial reperfusion as a consequence of the generation of oxygen free radicals, loss of cation homeostasis, depletion of energy stores, and changes in subcellular activities. The reperfusion injury may cause in the death of cardiac myocytes that were still viable immediately before myocardial reperfusion. This form of myocardial injury, by itself can induce cardiomyocyte death and increase infarct size. During acute ischemia the relative substrate concentration is the prime factor defining preference and utilization rate. Allosteric enzyme regulation and protein phosphorylation cascades, partially controlled by hormones such as insulin, modulate the concentration effect; together they provide short-term adjustments of cardiac energy metabolism. The expression of metabolic genes is also dynamically regulated in response to developmental and (patho)physiological conditions, leading to long-term adjustments. Specific nuclear receptor transcription factors and co-activators regulate the expression of these genes. Understanding the functional role of these changes is critical for developing the concept of metabolic intervention for heart disease. The paper will review the alterations in energy metabolism that occur during acute and chronic ischemia.
Keywords: Cardiac metabolism, myocardial ischemia, oxidative phosphorylation, beta oxidation, glycolysis
Current Pharmaceutical Design
Title: Cardiac Metabolism in Myocardial Ischemia
Volume: 14 Issue: 25
Author(s): Giuseppe M.C. Rosano, Massimo Fini, Giuseppe Caminiti and Giuseppe Barbaro
Affiliation:
Keywords: Cardiac metabolism, myocardial ischemia, oxidative phosphorylation, beta oxidation, glycolysis
Abstract: Myocardial ischemia occurs for a mismatch between blood flow and metabolic requirements, when the rate of oxygen and metabolic substrates delivery to the myocardium is insufficient to meet the myocardial energy requirements for a given myocardial workload. During ischemia, substantial changes occur in cardiac energy metabolism, as a consequence of the reduced oxygen availability. Some of these metabolic changes are beneficial and may help the heart adapt to the ischemic condition. However, most of the changes are maladaptive and contribute to the severity of the ischemic injury leading stunned or hibernating myocardium, cell death and ultimately to contractile disfuction. Dramatic changes in cardiac metabolism and contractile function, also occur during myocardial reperfusion as a consequence of the generation of oxygen free radicals, loss of cation homeostasis, depletion of energy stores, and changes in subcellular activities. The reperfusion injury may cause in the death of cardiac myocytes that were still viable immediately before myocardial reperfusion. This form of myocardial injury, by itself can induce cardiomyocyte death and increase infarct size. During acute ischemia the relative substrate concentration is the prime factor defining preference and utilization rate. Allosteric enzyme regulation and protein phosphorylation cascades, partially controlled by hormones such as insulin, modulate the concentration effect; together they provide short-term adjustments of cardiac energy metabolism. The expression of metabolic genes is also dynamically regulated in response to developmental and (patho)physiological conditions, leading to long-term adjustments. Specific nuclear receptor transcription factors and co-activators regulate the expression of these genes. Understanding the functional role of these changes is critical for developing the concept of metabolic intervention for heart disease. The paper will review the alterations in energy metabolism that occur during acute and chronic ischemia.
Export Options
About this article
Cite this article as:
Rosano M.C. Giuseppe, Fini Massimo, Caminiti Giuseppe and Barbaro Giuseppe, Cardiac Metabolism in Myocardial Ischemia, Current Pharmaceutical Design 2008; 14 (25) . https://dx.doi.org/10.2174/138161208786071317
DOI https://dx.doi.org/10.2174/138161208786071317 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Current Trends and Prospective Role of Flavonoids and Flavones as Anticancer Agents: A Review
Current Nutrition & Food Science Fluoroquinolones: Blessings Or Curses
Current Drug Targets Derivatives of 1,2,3,4-tetrahydroisoquinoline-7-carboxylic Acid as Novel Fibrinogen Receptor Antagonists
Medicinal Chemistry Oat β-Glucan Reduces Serum LDL Cholesterol in Humans with Serum LDL Cholesterol <160mg/dL
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Epigenetic Regulation of Osteogenic Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Epidemiology of Vitamin D and Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety Discovery of New Biomarkers of Cancer Using Proteomics Technology
Current Cancer Therapy Reviews Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy)
Current Pharmaceutical Design Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued) Chemokines in Cardiovascular Remodeling: Clinical and Therapeutic Implications
Current Molecular Medicine Opioid-induced Cardioprotection
Current Pharmaceutical Design Myocardial Tissue Engineering and Heart Muscle Repair
Current Pharmaceutical Biotechnology Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Big Data Analyses for Continuous Evaluation of Pharmacotherapy: A Proof of Principle with Doxapram in Preterm Infants
Current Pharmaceutical Design Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Drug Repositioning: A Monetary Stratagem to Discover a New Application of Drugs
Current Drug Discovery Technologies